NEUROSENSE THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHTue, 07 Apr 2026 10:45:54 +0200https://images.finanzen.net/images/finanzen_net_neu.gifNEUROSENSE THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netWorld-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SABThu, 08 Jan 2026 14:45:00 +0100https://www.finanzen.net/nachricht/aktien/world-renowned-alzheimer-s-expert-prof-steven-arnold-joins-neurosense-sab-15402156

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026

CAMBRIDGE, Mass., ]]>https://www.finanzen.net/nachricht/aktien/world-renowned-alzheimer-s-expert-prof-steven-arnold-joins-neurosense-sab-15402156NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 StudyMon, 22 Dec 2025 15:17:00 +0100https://www.finanzen.net/nachricht/aktien/neurosense-confirms-favorable-safety-and-tolerability-of-primec-in-an-alzheimer-s-phase-2-study-15374644

Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026

CAMBRIDGE, ...

]]>https://www.finanzen.net/nachricht/aktien/neurosense-confirms-favorable-safety-and-tolerability-of-primec-in-an-alzheimer-s-phase-2-study-15374644NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026Thu, 04 Dec 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/neurosense-to-hold-pre-nds-meeting-with-health-canada-in-april-2026-15335164

CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- ]]>https://www.finanzen.net/nachricht/aktien/neurosense-to-hold-pre-nds-meeting-with-health-canada-in-april-2026-15335164NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALSMon, 24 Nov 2025 15:56:00 +0100https://www.finanzen.net/nachricht/aktien/neurosense-receives-fda-clearance-to-initiate-pivotal-phase-3-trial-for-primec-in-als-15309026

CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- ]]>https://www.finanzen.net/nachricht/aktien/neurosense-receives-fda-clearance-to-initiate-pivotal-phase-3-trial-for-primec-in-als-15309026NeuroSense to Host Investor Webinar on December 8, 2025Mon, 03 Nov 2025 15:15:00 +0100https://www.finanzen.net/nachricht/aktien/neurosense-to-host-investor-webinar-on-december-8-2025-15176729

Business, regulatory and clinical updates will be provided

CAMBRIDGE, Mass., ]]>https://www.finanzen.net/nachricht/aktien/neurosense-to-host-investor-webinar-on-december-8-2025-15176729